Watson Pharmaceuticals WPI
-
Watson Pharmaceuticals ([[WPI]] +2.8%) gains on an upgrade to Outperform on valuation at Wells Fargo. Wells says that on deeper analysis, it has higher confidence in the company's ability to hit EPS ...
Watson Pharmaceuticals ( WPI +2.8% ) gains on an upgrade to Outperform on valuation at Wells Fargo. Wells says that on deeper analysis, it has higher …
-
Buckingham says Watson Pharmaceuticals ([[WPI]] -1.3%) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo ([[ENDP]] ...
Buckingham says Watson Pharmaceuticals ( WPI -1.3% ) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions …
-
New Morningstar Analyst Report - Watson Pharmaceuticals Inc.
… with shareholder interests, in our opinion. Upon closing of the recently announced Actavis acquisition, Watson Pharmaceuticals will become the third-largest global generic drug manufacturer. Post merger, international sales will represent …
-
Pfizer Set To Surge On 3 New Drug Candidates
… going. But the patent has expired , and since November 30, 2011 there have been generics available from Watson Pharmaceuticals ( WPI ) and Ranbaxy Laboratories, with more certainly to come. Sales of Lipitor peaked at 12.8 billion in 2008 …
-
Watson Has Double-Digit Upside, But Peers Are 'Strong Buys'
… however, the sector is by and large undervalued. In this article, I will run you through my DCF model on Watson Pharmaceuticals ( WPI ) and then triangulate the result with a review of the fundamentals against Pfizer and Novartis ( NVS …
-
Novartis: A Deeply Undervalued Buy At $54
… offs. Furthermore, that number does not include Pfizer's ( PFE ) $11.8 billion sale of its infant nutrition business to Nestlé. The acquisition ticker has been busy. Just last week, Watson Pharmaceuticals Complete Story »
-
Watson Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Watson Pharmaceuticals ( WPI ) Q1 2012 Earnings Call April 30, 2012 8:30 am ET Executives Patricia L. Eisenhaur - Vice President of Investor Relations …
-
UPDATE 2-Watson profit tops Wall Street estimate
April 30 (Reuters) - Watson Pharmaceuticals Inc posted higher-than-expected quarterly profit on Monday, as generic versions of the Lipitor cholesterol fighter and Lovenox blood thinner helped revenue soar by 74 percent.
-
Watson Pharmaceuticals (WPI): Q1 EPS of $1.64 beats by $0.04. Revenue of $1.52B (+73.9% Y/Y) beats by $40M. (PR)
Watson Pharmaceuticals ( WPI ): Q1 EPS of $1.64 beats by $0.04 . Revenue of $1.52B (+73.9% Y/Y) beats by $40M . ( PR ) Post your comment!
-
Watson profit tops Wall Street estimate
April 30 (Reuters) - Watson Pharmaceuticals Inc posted higher-than-expected quarterly profit on Monday, as generic versions of the Lipitor cholesterol fighter and Lovenox blood thinner helped revenue soar by 74 percent.